Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 8, 2007

Zyomyx to Develop T-Cell Counting Tool for Use in Developing Countries

  • The Imperial College London selected Zyomyx to work on a new treatment management tool for HIV/AIDS patients in developing countries. The company will codevelop a test to count CD4+ T-lymphocytes in blood.

    Zyomyx will receive milestone-dependent payments from Imperial College over the next four years for the development of this technology. Upon successful completion of the development program, the company intends to manufacture the resulting product for global release.

    "The absence of inexpensive, rapid, and robust CD4-counting tools jeopardizes global initiatives for fighting AIDS," remarks Peter Wagner, Ph.D., president and CEO of the company. “The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development and launch of an advanced but simple and inexpensive CD4 cell counting product that will meet the demanding specifications for use in developing countries.”

    Imperial College's CD4 Initiative is funded by the Bill & Melinda Gates Foundation.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »